Over the past five years, the Chinese pharmaceutical industry has experienced new opportunities and challenges with the implementation of a new round of medical reforms nationwide. Since the outbreak of the COVID-19 pandemic in 2019, the increasing awareness of health and the continuous demand for medical services have led to a sustained growth in demand for traditional Chinese medicine products and services in China. This study takes a comprehensive fundamental analysis approach, incorporating relevant knowledge from finance, to examine the financial indicators and development of Yiling Pharmaceutical Co., Ltd., a typical company in the pharmaceutical industry. Through financial statement analysis, the profitability of Yunnan Baiyao is assessed, along with the prediction of debt-paying ability during the evaluation process. Lastly, a fundamental analysis is conducted to summarize the strengths and weaknesses of Yiling Pharmaceutical Co., resulting in the conclusion of its investment value.